Association of a beta-2 adrenoceptor (ADRB2) gene variant with a blunted in vivo lipolysis and fat oxidation

J.W. Jocken*, E.E. Blaak, S.L.H. Schiffelers, P. Arner, M.A. van Baak, W.H. Saris

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

235 Downloads (Pure)


Background and aims:Obesity is associated with a blunted beta-adrenoceptor-mediated lipolysis and fat oxidation. We investigated whether polymorphisms in codon 16, 27 and 164 of the beta (2)-adrenoceptor gene (ADRB2) and exon 10 of the G protein beta (3)-subunit gene (GNB3) are associated with alterations in in vivo lipolysis and fat oxidation.Design and methods:Sixty-five male and 43 female overweight and obese subjects (body mass index (BMI) range: 26.1-48.4 kg/m(2)) were included. Energy expenditure (EE), respiratory quotient (RQ), circulating free fatty acid (FFA) and glycerol levels were determined after stepwise infusion of increasing doses of the non-selective beta-agonist isoprenaline (ISO).Results:In women, the Arg16 allele of the ADRB2 gene was associated with a blunted increase in circulating FFA, glycerol and a decreased fat oxidation during ISO stimulation. In men, the Arg16 allele was significantly associated with a blunted increase in FFA but not in glycerol or fat oxidation.Conclusion:These results suggest that genetic variation in the ADRB2 gene is associated with disturbances in in vivo beta-adrenoceptor-mediated lipolysis and fat oxidation during beta-adrenergic stimulation in overweight and obese subjects; these effects are influenced by gene-gender interactions.International Journal of Obesity advance online publication, 28 November 2006; doi:10.1038/sj.ijo.0803499.
Original languageEnglish
Pages (from-to)813-819
JournalInternational Journal of Obesity
Issue number5
Publication statusPublished - 1 Jan 2007

Cite this